The Amyloidoses

  • Pasha Sarraf
  • Jonathan Kay


  • The prevalence of amyloid diseases varies in different geographic areas. Alzheimer’s disease is the most common form of localized amyloidosis, while AL amyloidosis is the most common systemic form of amyloidosis in the United States, while AA amyloidosis is the most common form worldwide.

  • Amyloid fibrils resemble a woven cable and are deposited in tissues depending of the specific causative protein. Amyloid deposits do not cause an inflammatory reaction, but interfere with the function of surrounding tissues.

  • Clinical manifestations vary according to the type of amyloid disease.

  • Diagnosis is made by recognition of deposits with a characteristic “apple green” birefringence under polarizing microscopy and the specific subunit protein by immunohistochemistry.

  • ■ Treatment is directed toward reducing production of aberrant proteins or surgical removal of amyloid deposits or affected organs.


Familial Mediterranean Fever Carpal Tunnel Syndrome Amyloid Deposit Cardiac Amyloidosis Systemic Amyloidosis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Sipe JD, Cohen AS. Review: history of the amyloid fibril. J Struct Biol 2000;130:88–98.PubMedCrossRefGoogle Scholar
  2. 2.
    Majno G, Joris I. Extracellular pathology. In: Cells, tissues, and disease: principles of general pathology. Oxford: Oxford University Press; 2004:250–267.Google Scholar
  3. 3.
    Pepys MB. Amyloidosis. Annu Rev Med 2006;57:223–241.PubMedCrossRefGoogle Scholar
  4. 4.
    Merlini G, Bellotti V. Mechanisms of disease: molecular mechanisms of amyloidosis. N Engl J Med 2003;349: 583–596.PubMedCrossRefGoogle Scholar
  5. 5.
    Buxbaum J. The amyloidoses. In: Klippel JH, Dieppe PA, eds. Rheumatology. Mosby yearbook. 1998;8.27.1–8.27.10.Google Scholar
  6. 6.
    Kyle RA, Linos A, Beard CM, et al. Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989. Blood 1992;79: 1817–1822.PubMedGoogle Scholar
  7. 7.
    Kyle RA, Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol 1995;32:45–59.PubMedGoogle Scholar
  8. 8.
    Skinner M, Anderson J, Simms R, et al. Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, and colchicine versus colchi cine only. Am J Med 1996;100:290–298.PubMedCrossRefGoogle Scholar
  9. 9.
    Kyle RA, Gertz MA, Greipp PR, et al. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med 1997;336:1202–1207.PubMedCrossRefGoogle Scholar
  10. 10.
    Comenzo RL. Amyloidosis. Curr Treat Options Oncol 2006;7:225–236.PubMedCrossRefGoogle Scholar
  11. 11.
    Gillmore JD, Lovat LB, Persey MR, Pepys MB, Hawkins PN. Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet 2001;358:24–29.PubMedCrossRefGoogle Scholar
  12. 12.
    Booth DR, Booth SE, Gillmore JD, Hawkins PN, Pepys MB. SAA1 alleles as risk factors in reactive systemic AA amyloidosis. Amyloid 1998;5:262–265.PubMedGoogle Scholar
  13. 13.
    Benson MD. Amyloidosis. In: Koopman WJ, Moreland LW, eds. Arthritis and allied conditions: a textbook of rheumatology. Philadelphia: Lippincott Williams & Wilkins; 2005:1933–1960.Google Scholar
  14. 14.
    Kay J. β2-microglobulin amyloidosis. Int J Exp Clin Invest 1997;4:187–211.Google Scholar
  15. 15.
    Miyata T, Inagi R, Iida Y, et al. Involvement of beta 2-microglobulin modified with advanced glycation end products in the pathogenesis of hemodialysis-associated amyloidosis. Induction of human monocyte chemotaxis and macrophage secretion of tumor necrosis factor-alpha and interleukin-1. J Clin Invest 1994;93:521–528.PubMedCrossRefGoogle Scholar
  16. 16.
    Georgiades CS, Neyman EG, Barish MA, Fishman EK. Amyloidosis: review and CT manifestations. Radiographics 2004;24:405–416.PubMedCrossRefGoogle Scholar
  17. 17.
    Hawkins PN, Lavender JP, Pepys MB. Evaluation of systemic amyloidosis by scintigraphy with 123I-labeled serum amyloid P component. N Engl J Med 1990;323:508–513.PubMedCrossRefGoogle Scholar
  18. 18.
    Shah KB, Inoue Y, Mehra MR. Amyloidosis and the heart: a comprehensive review. Arch Intern Med 2006;166:1805–1813.PubMedCrossRefGoogle Scholar
  19. 19.
    Falk RH, Plehn JF, Deering T, et al. Sensitivity and specificity of the echocardiographic features of cardiac amyloidosis. Am J Cardiol 1987;59:418–422.PubMedCrossRefGoogle Scholar
  20. 20.
    Maceira AM, Joshi J, Prasad SK, et al. Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation 2005;111:186–193.PubMedCrossRefGoogle Scholar
  21. 21.
    Westermark P, Stenkvist B. A new method for the diagnosis of systemic amyloidosis. Arch Intern Med 1973;132: 522–523.PubMedCrossRefGoogle Scholar
  22. 22.
    Hachulla E, Janin A, Flipo RM, et al. Labial salivary gland biopsy is a reliable test for the diagnosis of primary and secondary amyloidosis. A prospective clinical and immunohistologic study in 59 patients. Arthritis Rheum 1993;36:691–697.PubMedCrossRefGoogle Scholar
  23. 23.
    Comenzo RL, Zhou P, Fleisher M, Clark B, Teruya-Feldstein J. Seeking confidence in the diagnosis of systemic AL (Ig light-chain) amyloidosis: patients can have both monoclonal gammopathies and hereditary amyloid proteins. Blood 2006;107:3489–3491.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2008

Authors and Affiliations

  • Pasha Sarraf
    • 1
    • 2
  • Jonathan Kay
    • 3
  1. 1.Massachusetts General HospitalBostonUSA
  2. 2.Department of Medicine, Division of Rheumatology, Allergy and ImmunologyMassachusetts General HospitalBostonUSA
  3. 3.Department of MedicineHarvard Medical SchoolBostonUSA

Personalised recommendations